These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38004634)

  • 1. Phylogenetic Analysis and Emerging Drug Resistance against Different Nucleoside Analogues in Hepatitis B Virus Positive Patients.
    Gohar M; Rehman IU; Ullah A; Khan MA; Yasmin H; Ahmad J; Butt S; Ahmad A
    Microorganisms; 2023 Oct; 11(11):. PubMed ID: 38004634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation into drug-resistant mutations of HBV from 845 nucleoside/nucleotide analogue-naive Chinese patients with chronic HBV infection.
    Li X; Liu Y; Zhao P; Wang Y; Chen L; Xin S; Zhang XX; Xu D
    Antivir Ther; 2015; 20(2):141-7. PubMed ID: 24992206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis B virus mutation pattern rtL180M+A181C+M204V may contribute to entecavir resistance in clinical practice.
    Liu Y; Zhou Y; Li X; Niu M; Chen R; Shao J; Si L; Luo D; Lin Y; Li L; Zhang K; Xiao X; Xu Z; Liu M; Lu M; Zoulim F; Xu D
    Emerg Microbes Infect; 2019; 8(1):354-365. PubMed ID: 30866789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutations.
    Cassino L; Benetti S; Fay F; Tanno H; Quarleri J
    BMC Infect Dis; 2011 Jun; 11():178. PubMed ID: 21696601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.
    Brunelle MN; Jacquard AC; Pichoud C; Durantel D; Carrouée-Durantel S; Villeneuve JP; Trépo C; Zoulim F
    Hepatology; 2005 Jun; 41(6):1391-8. PubMed ID: 15915463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B virus genotypes and resistance mutations in patients under long term lamivudine therapy: characterization of genotype G in Brazil.
    Bottecchia M; Souto FJ; O KM; Amendola M; Brandão CE; Niel C; Gomes SA
    BMC Microbiol; 2008 Jan; 8():11. PubMed ID: 18211717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistant mutations within the hepatitis B virus reverse transcriptase sequence in treatment failure patients with chronic HBV infection in Vietnam.
    Nguyen TK; Van Le D
    J Glob Antimicrob Resist; 2023 Jun; 33():35-41. PubMed ID: 36849052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B virus rtA181T/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T/sW172* mutation.
    Zhao L; Li X; Cheng Y; Chen R; Shao J; Zhou Y; Li Q; Liao H; Zhao Y; Liu L; Su H; Liu Y; Liu Y; Xu D
    Antiviral Res; 2018 Jun; 154():26-34. PubMed ID: 29630974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple drug-resistant HBV mutation may contribute to poor response of adefovir + entecavir in entecavir-resistant patients.
    Shao J; Liu Y; Liu LM; Chen R; Zhao L; Zhou Y; Li L; Li X; Li J; Xu D
    J Infect Dev Ctries; 2021 Jan; 15(1):131-140. PubMed ID: 33571155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients.
    Margeridon-Thermet S; Shulman NS; Ahmed A; Shahriar R; Liu T; Wang C; Holmes SP; Babrzadeh F; Gharizadeh B; Hanczaruk B; Simen BB; Egholm M; Shafer RW
    J Infect Dis; 2009 May; 199(9):1275-85. PubMed ID: 19301976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection and analysis of resistance mutations of hepatitis B virus.
    He X; Wang F; Huang B; Chen P; Zhong L
    Int J Clin Exp Med; 2015; 8(6):9630-9. PubMed ID: 26309637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Investigation of baseline antiviral resistance in treatment-naive chronic hepatitis B cases].
    Ergünay K; Kahramanoğlu Aksoy E; Simşek H; Alp A; Sener B; Tatar G; Us D; Hasçelik G
    Mikrobiyol Bul; 2013 Oct; 47(4):628-35. PubMed ID: 24237431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CMCdG, a Novel Nucleoside Analog with Favorable Safety Features, Exerts Potent Activity against Wild-Type and Entecavir-Resistant Hepatitis B Virus.
    Higashi-Kuwata N; Hayashi S; Das D; Kohgo S; Murakami S; Hattori SI; Imoto S; Venzon DJ; Singh K; Sarafianos SG; Tanaka Y; Mitsuya H
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a novel long-acting 4'-modified nucleoside reverse transcriptase inhibitor against HBV.
    Higashi-Kuwata N; Hayashi S; Kumamoto H; Ogata-Aoki H; Das D; Venzon D; Hattori SI; Bulut H; Hashimoto M; Otagiri M; Takamune N; Kishimoto N; Davis DA; Misumi S; Kakuni M; Tanaka Y; Mitsuya H
    J Hepatol; 2021 May; 74(5):1075-1086. PubMed ID: 33333207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern.
    Inoue J; Ueno Y; Wakui Y; Niitsuma H; Fukushima K; Yamagiwa Y; Shiina M; Kondo Y; Kakazu E; Tamai K; Obara N; Iwasaki T; Shimosegawa T
    J Viral Hepat; 2011 Mar; 18(3):206-15. PubMed ID: 20367795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility of hepatitis B virus to lamivudine restored by resistance to adefovir.
    Zaaijer HL; Takkenberg RB; Weegink CJ; Rebers SP; Menting S; Reesink HW; Schinkel J; Molenkamp R
    J Med Virol; 2009 Mar; 81(3):413-6. PubMed ID: 19152408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serologic and genotypic characterization of hepatitis B virus in HIV-1 infected patients from South West and Littoral Regions of Cameroon.
    Magoro T; Gachara G; Mavhandu L; Lum E; Kimbi HK; Ndip RN; Bessong P
    Virol J; 2016 Oct; 13(1):178. PubMed ID: 27769271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Resistance mutation patterns of hepatitis B virus in patients with suboptimal response to adefovir dipivoxil therapy after lamivudine resistance].
    Wu ZP; Hang T; Gao YT; Li Y; Liu T; Jing L; Liu L; Du Z
    Zhonghua Gan Zang Bing Za Zhi; 2010 Jul; 18(7):498-501. PubMed ID: 20678438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Detection of resistance mutations in chronic hepatitis B patients receiving antiviral therapy for over one year].
    Aydoğan S; Ergünay K; Balaban Y; Alp A; Simşek H; Tatar G; Hasçelik G; Us D
    Mikrobiyol Bul; 2013 Jul; 47(3):472-81. PubMed ID: 23971924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.